Chinese conglomerate Fosun International will buy the remaining stake in Shanghai Henlius Biotech it does not already own in a deal that values the Hong Kong-listed drugmaker at HK$13.37 billion ($1.71 billion), the companies said on Monday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
